Top Stories
Despite the negative market reaction, Cue says it is advancing CUE-221 into a Phase IIb/III study in chronic spontaneous urticaria and in a Phase II food allergy study.
Iambic’s Enchant v3 will be used by AbbVie across immunology, neuroscience and oncology, marking the AI firm's third large pharma partnership this year after Takeda and Bayer deals.
ADARx is also likely to raise an additional $80 million in a private placement from AbbVie.
Phase III data show the experimental cagrilintide and semaglutide combo can outperform a lower-dose of Lilly's Zepbound on weight loss in people with type 2 diabetes.
Shares fell more than 5% as the company detailed plans to revive fortunes in the obesity drug market and diversify beyond its key areas.
Conference News
Early Data for T-MAXIMUM's B7-H3 Allogeneic CAR-T in Brain Metastases Presented at WCLC 2026BEIJING, Sept. 21, 2026 /PRNewswire/ -- As B7-H3 ADCs reshape the second-line treatment landscape for small ...
New data revealed that healthcare providers prioritize drowsiness risk, duration of available data demonstrating long-term response and drug-drug interaction profile when selecting a treatment for tar...
NANJING, China, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that its pivotal registrational Phase IIb stu...
Phase 3 data for intismeran autogene in the adjuvant treatment of patients with resected stage IIB-IV melanoma selected for presentation at a Presidential SymposiumModerna to host an investor event vi...
Presentations will highlight Phase 2b OPTI-2 findings demonstrating the potential of HDV-insulin lispro to maintain glycemic control while reducing hypoglycemia in adults with type 1 diabetesNew expos...
